Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

The Fred & Pamela Buffett Cancer Center has named Kathleen N. Moore as deputy director and director of Phase I Oncology Trials.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Computational model measures key aging metric from routine biopsies, Sanford Burnham study finds

A computational tool infers changes occurring at the ends of the chromosomes housing our DNA, which it does so by detecting structural alterations in cells and tissues captured in images taken of routine medical biopsies, according to a study by scientists at Sanford Burnham Prebys Medical Discovery Institute.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Computational biology tool automates and standardizes genome sequencing analysis, Sanford Burnham study finds

In a single experiment, scientists can decipher the entire genomes of many patient samples, animal models, or cultured cells. To fully realize the potential to study biology at this scale, researchers must be equipped to analyze the titanic troves of data generated by these new methods.

March 20, 2026

Vol.52 No.11

Drugs & Targets

START, Trialing collaborate to expand access to oncology clinical trials across Europe

The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced a strategic partnership with Trialing, a platform dedicated to connecting physicians and patients to clinical trials, helping physicians rapidly identify, evaluate, and refer patients to appropriate studies.

March 20, 2026

Vol.52 No.11

Conversation with The Cancer Letter

Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”

Five years ago, Tyler Jacks took on a new challenge, becoming president of Break Through Cancer, a foundation that has pledged to spend at least $500 million to support research projects across top tier cancer centers.

March 13, 2026

Vol.52 No.10

By Paul Goldberg

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

YOU MAY BE INTERESTED IN

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Computational model measures key aging metric from routine biopsies, Sanford Burnham study finds

Computational biology tool automates and standardizes genome sequencing analysis, Sanford Burnham study finds

START, Trialing collaborate to expand access to oncology clinical trials across Europe

Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”

Renew today!

Subscriber content

Never miss an issue!

Login